Author(s): Scheinberg M, CastaedaHernndez G, Scheinberg M, CastaedaHernndez G
Abstract Share this page
Abstract Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
This article was published in Arthritis Res Ther
and referenced in Journal of Clinical & Experimental Dermatology Research